Subject matters | Details | Categories |
---|---|---|
Health
|
Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
|
Policies or Program
|
Health
|
Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
|
Policies or Program
|
Health
|
Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
|
Policies or Program
|
Economic Development, Research and Development, Science and Technology, Taxation and Finance
|
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
|
Policies or Program
|
Health
|
Policies aimed at facilitating generic drug repurposing.
|
Policies or Program
|
Economic Development, Health, Industry
|
Policies aimed at reinforcing pharmaceutical supply chain.
|
Policies or Program
|
Economic Development, Health, Industry
|
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
|
Grant, Contribution or Other Financial Benefit
|
Pharmascience Inc. is a Canadian-owned pharmaceutical company specializing in the manufacturing and distribution of generic, innovative, and consumer brand pharmaceutical products in Canada
Martin Arès, Chief Executive Officer
End date of the last completed financial year: 2024-05-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
Innovation, Science and Economic Development Canada (ISED) | $0.00 | Yes |
Investissement Québec | $0.00 | Yes |
Address:
6111 Royalmount avenue, suite 100
Montreal, QC H4P 2T4
Canada
Telephone number:
514-340-9800
Pharmascience Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking